Literature DB >> 10493833

Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders.

V Ling1, P W Wu, H F Finnerty, A H Sharpe, G S Gray, M Collins.   

Abstract

CTLA4 (CD152), a receptor for the B7 costimulatory molecules (CD80 and CD86), is considered a fundamental regulator of T-cell activation. In this paper, we present the complete primary structure of the mouse and human CTLA4 gene loci. Sequence comparison between the mouse and the human CTLA4 gene loci revealed a high degree of sequence conservation both for homologous noncoding regions (65-78% identity) and for coding regions (72-98% identity), with an overall score of 71% over the entire length of the two genes. Of the CTLA4 genomic regions aligned, five simple repetitive elements were found in the mouse locus, whereas two simple repetitive sequences were localized on the human locus. RNA blot analysis of mouse and human primary tissues indicated that both CTLA4 and T-cell receptor transcripts were found in most organs with generally higher levels in lymphoid tissues. The conservation of CTLA4 gene patterning raises the possibility that constrained gene evolution of CTLA4 may be linked to conserved transcriptional control of this locus. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493833     DOI: 10.1006/geno.1999.5930

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  17 in total

1.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis.

Authors:  Je-Min Choi; Seung-Hyung Kim; Jae-Hoon Shin; Thomas Gibson; Byoung-Seok Yoon; Dong-Ho Lee; Seung-Kyou Lee; Alfred L M Bothwell; Jong-Soon Lim; Sang-Kyou Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

3.  Differential expression of CTLA-4 among T cell subsets.

Authors:  C B Jago; J Yates; N Olsen Saraiva Câmara; R I Lechler; G Lombardi
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

4.  The genetic basis of primary biliary cirrhosis: premises, not promises.

Authors:  Pietro Invernizzi; M Eric Gershwin
Journal:  Gastroenterology       Date:  2008-09-04       Impact factor: 22.682

Review 5.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Authors:  Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 6.  Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.

Authors:  Jiu-Cheng Zhang; Wei-Dong Chen; Jean Bustamante Alvarez; Kelly Jia; Lei Shi; Qiang Wang; Ning Zou; Kai He; Hua Zhu
Journal:  Acta Pharmacol Sin       Date:  2018-07-10       Impact factor: 6.150

7.  CTLA-4 gene polymorphism and the risk of systemic lupus erythematosus in the Chinese population.

Authors:  Ahmad Taha Khalaf; Ji-Quan Song; Ting-Ting Gao; Xiang-Ping Yu; Tie-Chi Lei
Journal:  J Biomed Biotechnol       Date:  2011-09-11

8.  Structure-Function analysis of the CTLA-4 interaction with PP2A.

Authors:  Wendy A Teft; Thu A Chau; Joaquín Madrenas
Journal:  BMC Immunol       Date:  2009-04-30       Impact factor: 3.615

Review 9.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

Review 10.  CTLA-4 trafficking and surface expression.

Authors:  Elke Valk; Christopher E Rudd; Helga Schneider
Journal:  Trends Immunol       Date:  2008-05-09       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.